What is Sagis?
Sagis Diagnostics operates as a comprehensive diagnostics laboratory, offering a broad spectrum of services that encompass dermatopathology, podiatric pathology, toxicology, molecular pathology, and surgical cytopathology. The company distinguishes itself through its team of expert pathologists who employ advanced diagnostic methodologies to ensure high accuracy and a steadfast commitment to patient-centered care. Sagis primarily serves healthcare providers, including clinicians and doctors of podiatric medicine, by furnishing them with essential educational resources and expert consultation services. Their dedication to integrating the latest scientific advancements aims to facilitate precise diagnoses and ultimately enhance patient outcomes.
How much funding has Sagis raised?
Sagis has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Sagis
PPP
Public-Private Partnership
What's next for Sagis?
With the recent major strategic investment, Sagis is poised for accelerated growth and enhanced service delivery. The enterprise-level funding context suggests a phase of significant scaling, potentially involving the expansion of laboratory capabilities, the adoption of new diagnostic technologies, and the broadening of their market reach. This strategic capital infusion will likely empower Sagis to further solidify its position as a leader in specialized pathology services, driving innovation and improving diagnostic precision across its service lines.
See full Sagis company page
